Drugs / BNT162a1
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT04380701 | Apr 2020 → Jun 2021 | respiratory tract infectious disorder, viral infectious disease | BioNTech SE | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BNT162a1 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04380701 ↗ |
| Route | Intramuscular | “administered as intramuscular injection.” NCT04380701 ↗ |